Dive Brief: The Food and Drug Administration rejected an Akebia Therapeutics’ anemia pill vadadustat, the company announced Wednesday, over concerns the drug isn’t as safe as currently …

The upcoming FDA meeting is critical for FibroGen. CEO Enrique Conterno told analysts on a conference call this week that he believes the company has …